{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:32:13Z","timestamp":1759743133295},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Science and Technology Major of China of the 13th Five-Year Plan","award":["2018ZX10302104"],"award-info":[{"award-number":["2018ZX10302104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Toxoplasma encephalitis (TE) is one of the main opportunistic infections in acquired immunodeficiency syndrome (AIDS) patients, and represents a social burden due to its high prevalence and morbidity. Concomitant antiretroviral therapy (ART), together with effective anti- toxoplasma combination therapy, is an effective strategy to treat AIDS-associated TE (AIDS\/TE) patients. However, the timing for the initiation of ART after diagnosis of TE remains controversial. We therefore designed the present study to determine the optimal timing for ART initiation in AIDS\/TE patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design:<\/jats:title>\n            <jats:p>This trial is a 17-center, randomized, prospective clinical study with 2 parallel arms. A total of 200 participants will be randomized at a 1:1 ratio into the 2 arms: the early ART initiation (\u226414 days after TE diagnosis) arm and the deferred ART (&gt;14 days after TE diagnosis) arm. The primary outcome will be the difference of mortality between the 2 arms at 48 weeks. The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid &lt;50\u200acopies\/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This present trial aims to evaluate the optimal timing for ART initiation in AIDS\/TE patients, and will provide strong evidence for AIDS\/TE treatment should it be successful.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This trial was registered as one of the 12 trials under the name of a general project at the chictr.gov (http:\/\/www.chictr.org.cn\/showproj.aspx?proj=35362) on February 1, 2019, and the registration number of the general project is ChiCTR1900021195.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021141","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T18:04:42Z","timestamp":1595009082000},"page":"e21141","source":"Crossref","is-referenced-by-count":4,"title":["A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections"],"prefix":"10.1097","volume":"99","author":[{"given":"Yan-Ming","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Qiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2352-3018(15)00017-X","article-title":"AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study","volume":"2","author":"Lima","year":"2015","journal-title":"Lancet HIV"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrneurol.2016.149","article-title":"HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment","volume":"12","author":"Bowen","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1017\/S0031182017002189","article-title":"Understanding host\u2013parasite relationship: the immune central nervous system microenvironment and its effect on brain infections","volume":"145","author":"Adalid-Peralta","year":"2018","journal-title":"Parasitology"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2217\/fmb.09.89","article-title":"Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients","volume":"4","author":"Pereira-Chioccola","year":"2009","journal-title":"Future Microbiol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11904-012-0126-8","article-title":"When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!","volume":"9","author":"Grant","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12981-019-0250-2","article-title":"Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)","volume":"16","author":"Sch\u00e4fer","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4103\/0971-5916.92632","article-title":"HIV & immune reconstitution inflammatory syndrome (IRIS)","volume":"134","author":"Sharma","year":"2011","journal-title":"Ind J Med Res"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/apc.2005.19.626","article-title":"Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era","volume":"19","author":"Vidal","year":"2005","journal-title":"AIDS Patient Care & Stds"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1756-0500-6-146","article-title":"Toxoplasma encephalitis in HIV\/AIDS patients admitted to the Douala general hospital between 2004 and 2009: a cross sectional study","volume":"6","author":"Luma","year":"2013","journal-title":"BMC Res Notes"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PloS ONE"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:33:28Z","timestamp":1694828008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021141"}},"subtitle":["Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis"],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":10,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021141","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}